CSRxP Applauds Senate Action To Boost Drug Price Transparency For Consumers

Legislation Includes CSRxP-Supported Amendment Enabling HHS To Require Disclosure of Drug Prices in Direct-to-Consumer Advertising

The Campaign for Sustainable Rx Pricing issued the following statement after the Senate took action to enhance drug pricing transparency by passing legislation that included a CSRxP-supported amendment – introduced by Senator Dick Durbin (D-IL) and Senator Chuck Grassley (R-IA) – that would enable the Department of Health and Human Services to require disclosure of drug pricing information in direct-to-consumer advertising for prescription drugs:

“Tonight, the Senate tonight took an important step toward ensuring consumers have the information they need to make the health care decisions that are right for them. Combined with increased competition in the marketplace and a greater focus on higher-value, lower-cost choices, efforts to enhance transparency like this will help curb out-of-control drug prices and help patients find affordable treatment options.

“We appreciate the bipartisan leadership of Senators Durbin and Grassley, as well as the Administration, for advancing this proposal. We look forward to continuing to work with Congress and the Administration on bipartisan, market-based solutions that reduce prescription drug prices.”

###